These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 30779957)

  • 1. Angioedema following initiation of glecaprevir/pibrentasvir while on sitagliptin.
    Schneider A; Ramesh M
    J Allergy Clin Immunol Pract; 2019; 7(6):2068-2069. PubMed ID: 30779957
    [No Abstract]   [Full Text] [Related]  

  • 2. Glecaprevir/pibrentasvir-associated acute liver injury in non-cirrhotic, chronic HCV infection without HBV co-infection.
    Hammami MB; Aboushaar R; Alsabbagh E
    BMJ Case Rep; 2019 May; 12(5):. PubMed ID: 31129632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dead Meat: Glecaprevir/Pibrentasvir-Induced Statin Myonecrosis.
    Wong K; Podboy A; Lavezo J; Goel A
    Dig Dis Sci; 2020 Feb; 65(2):399-400. PubMed ID: 31894484
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
    Kosloski MP; Wang H; Pugatch D; Mensa FJ; Gane E; Lawitz E; Marbury TC; Preston RA; Kort J; Liu W
    Eur J Clin Pharmacol; 2019 Feb; 75(2):217-226. PubMed ID: 30341499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glecaprevir/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation.
    Caroleo B; Caroleo MC; Cimellaro A; Colangelo L; Perticone M; Di Mizio G; De Sarro G; Gallelli L
    Curr Drug Saf; 2019; 14(1):67-71. PubMed ID: 30444202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
    Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
    Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin for Type 2 diabetes: a 2015 update.
    Lee M; Rhee MK
    Expert Rev Cardiovasc Ther; 2015 Jun; 13(6):597-610. PubMed ID: 26000559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ
    Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
    Zeuzem S; Foster GR; Wang S; Asatryan A; Gane E; Feld JJ; Asselah T; Bourlière M; Ruane PJ; Wedemeyer H; Pol S; Flisiak R; Poordad F; Chuang WL; Stedman CA; Flamm S; Kwo P; Dore GJ; Sepulveda-Arzola G; Roberts SK; Soto-Malave R; Kaita K; Puoti M; Vierling J; Tam E; Vargas HE; Bruck R; Fuster F; Paik SW; Felizarta F; Kort J; Fu B; Liu R; Ng TI; Pilot-Matias T; Lin CW; Trinh R; Mensa FJ
    N Engl J Med; 2018 Jan; 378(4):354-369. PubMed ID: 29365309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older.
    Huff J; Andersen R
    Ann Pharmacother; 2020 Mar; 54(3):262-276. PubMed ID: 31537106
    [No Abstract]   [Full Text] [Related]  

  • 14. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.
    Skalli S; Wion-Barbot N; Baudrant M; Lablanche S; Benhamou PY; Halimi S
    Diabet Med; 2010 Apr; 27(4):486-7. PubMed ID: 20536525
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis.
    Wang X; Fan X; Deng H; Zhang X; Zhang K; Li N; Han Q; Lv Y; Liu Z
    Int J Antimicrob Agents; 2019 Dec; 54(6):780-789. PubMed ID: 31284039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.
    Atsukawa M; Tsubota A; Toyoda H; Takaguchi K; Nakamuta M; Watanabe T; Michitaka K; Ikegami T; Nozaki A; Uojima H; Fukunishi S; Genda T; Abe H; Hotta N; Tsuji K; Ogawa C; Tachi Y; Shima T; Shimada N; Kondo C; Akahane T; Aizawa Y; Tanaka Y; Kumada T; Iwakiri K
    Aliment Pharmacol Ther; 2019 May; 49(9):1230-1241. PubMed ID: 30873651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
    Gane E; Poordad F; Zadeikis N; Valdes J; Lin CW; Liu W; Asatryan A; Wang S; Stedman C; Greenbloom S; Nguyen T; Elkhashab M; Wörns MA; Tran A; Mulkay JP; Setze C; Yu Y; Pilot-Matias T; Porcalla A; Mensa FJ
    Clin Infect Dis; 2019 Oct; 69(10):1657-1664. PubMed ID: 30923816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin-associated angioedema.
    Gosmanov AR; Fontenot EC
    Diabetes Care; 2012 Aug; 35(8):e60. PubMed ID: 22826453
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world effectiveness and safety of glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C.
    Hsu SJ; Chiu MC; Fang YJ; Yang TH; Yu JJ; Chen CC; Kuo CC; Lee JY; Chen CH; Chen DS; Kao JH
    J Formos Med Assoc; 2019 Aug; 118(8):1187-1192. PubMed ID: 31279502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.
    Kosloski MP; Zhao W; Li H; Pugatch D; Asatryan A; Kort J; Mensa FJ; Liu W
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):779-789. PubMed ID: 30861340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.